Recent studies reported overexpression of RACGAP1 in several types of cancers (e.g., gastric cancer, colorectal cancer, uterine carcinosarcoma, hepatocellular carcinoma and epithelial ovarian cancer), and its aberrant expression was associated with poor prognosis in patients with these cancers [35,36,37,38,39]. Here, RACGAP1 is linked to hepatocellular carcinoma.